This bill aims to enhance Medicare coverage for services related to hereditary cancer, focusing on prevention and early detection. It mandates coverage for germline mutation testing for individuals who have a personal or family history of a hereditary cancer gene mutation or a history otherwise suspicious for hereditary cancer. This testing must adhere to evidence-based clinical practice guidelines developed by nationally recognized oncology professional organizations, with the least restrictive guidelines applying in cases of conflict. Furthermore, the legislation expands Medicare to cover certain risk-reducing surgeries for individuals identified as high-risk based on these guidelines, deeming such procedures reasonable and necessary for illness treatment. For individuals confirmed to have a hereditary cancer gene mutation through genetic testing, the bill requires an increase in the frequency of evidence-based cancer screenings . These screenings, which include mammography, MRI, colonoscopy, and PSA testing, must align with clinical practice guidelines or occur at least annually, ensuring more proactive monitoring for high-risk beneficiaries.